NCT04232423View on ClinicalTrials.gov

Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis

PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

June 30, 2021

Study Completion Date

September 30, 2021

Conditions
Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis
Interventions
DRUG

Olanzapine 10 Mg ORAL TABLET

"* Olanzapine 10 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 10 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"

DRUG

Olanzapine 5 Mg ORAL TABLET

"* Olanzapine 5 mg orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Olanzapine 5 mg orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"

DRUG

Placebo ORAL TABLET

"* Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4"

Trial Locations (1)

10400

Rajavithi hospital, Bangkok

All Listed Sponsors
lead

Department of Medical Services Ministry of Public Health of Thailand

OTHER_GOV

NCT04232423 - Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis | Biotech Hunter | Biotech Hunter